119 related articles for article (PubMed ID: 7137035)
1. Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway.
Wellens HJ; Braat S; Brugada P; Gorgels AP; Bär FW
Am J Cardiol; 1982 Nov; 50(5):1087-9. PubMed ID: 7137035
[TBL] [Abstract][Full Text] [Related]
2. Value of the ajmaline-procainamide test to predict the effect of long-term oral amiodarone on the anterograde effective refractory period of the accessory pathway in the Wolff-Parkinson-White syndrome.
Brugada P; Dassen WR; Braat S; Gorgels AP; Wellens HJ
Am J Cardiol; 1983 Jul; 52(1):70-2. PubMed ID: 6858931
[TBL] [Abstract][Full Text] [Related]
3. Use of ajmaline in patients with the Wolff-Parkinson-White syndrome to disclose short refractory period of the accessory pathway.
Wellens HJ; Bär FW; Gorgels AP; Vanagt EJ
Am J Cardiol; 1980 Jan; 45(1):130-3. PubMed ID: 7350760
[TBL] [Abstract][Full Text] [Related]
4. Procainamide infusion test: inability to identify patients with Wolff-Parkinson-White syndrome who are potentially at risk of sudden death.
Fananapazir L; Packer DL; German LD; Greer GS; Gallagher JJ; Pressley JC; Prystowsky EN
Circulation; 1988 Jun; 77(6):1291-6. PubMed ID: 3370769
[TBL] [Abstract][Full Text] [Related]
5. Value of a revised procainamide test in the Wolff-Parkinson-White syndrome.
Boahene KA; Klein GJ; Sharma AD; Yee R; Fujimura O
Am J Cardiol; 1990 Jan; 65(3):195-200. PubMed ID: 2296888
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of noninvasive tests for identifying patients with preexcitation syndrome at risk of rapid ventricular response.
Critelli G; Gallagher JJ; Perticone F; Coltorti F; Monda V; Condorelli M
Am Heart J; 1984 Oct; 108(4 Pt 1):905-9. PubMed ID: 6486001
[TBL] [Abstract][Full Text] [Related]
7. Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway.
Wellens HJ; Bär FW; Dassen WR; Brugada P; Vanagt EJ; Farré J
Am J Cardiol; 1980 Oct; 46(4):665-9. PubMed ID: 7416026
[TBL] [Abstract][Full Text] [Related]
8. Effects of magnesium and potassium on Wolff-Parkinson-White syndrome.
Sideris AM; Galiatsu E; Filippatos GS; Kappos K; Anthopoulos LP
J Electrocardiol; 1996 Jan; 29(1):11-5. PubMed ID: 8808520
[TBL] [Abstract][Full Text] [Related]
9. Transesophageal versus intracardiac atrial stimulation in assessing anterograde conduction properties of the accessory pathway in Wolff-Parkinson-White syndrome.
Favale S; Minafra F; Massari V; Tritto M; Rizzon P
Int J Cardiol; 1991 Feb; 30(2):209-14. PubMed ID: 2010244
[TBL] [Abstract][Full Text] [Related]
10. Two false-negative responses to the ajmaline test in the Wolff-Parkinson-White syndrome.
Cavalli A; Maggioni A; Tusa M; Volpi A
Pacing Clin Electrophysiol; 1985 Nov; 8(6):832-7. PubMed ID: 2415936
[TBL] [Abstract][Full Text] [Related]
11. [Electrophysiological effects of chloroacetyl ajmaline in Wolff-Parkinson-White syndrome].
Touboul P; Gressard A; Atallah G; Chatelain MT; Delahaye JP
Arch Mal Coeur Vaiss; 1978 Jul; 71(7):808-15. PubMed ID: 102281
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome.
Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T
Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867
[TBL] [Abstract][Full Text] [Related]
13. Comparison of exercise and ajmaline tests with electrophysiologic study in the Wolff-Parkinson-White syndrome.
Eshchar Y; Belhassen B; Laniado S
Am J Cardiol; 1986 Apr; 57(10):782-6. PubMed ID: 3962865
[TBL] [Abstract][Full Text] [Related]
14. Effect of procaine amide, quinidine, and ajmaline in the Wolff-Parkinson-White syndrome.
Wellens HJ; Durrer D
Circulation; 1974 Jul; 50(1):114-20. PubMed ID: 4835257
[No Abstract] [Full Text] [Related]
15. Diagnosis of dual accessory pathways by ajmaline test.
Belhassen B; Bar-David S; Laniado S
Cardiology; 1989; 76(1):53-7. PubMed ID: 2706645
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of intravenous procainamide on anterograde and retrograde accessory pathway refractoriness.
Leitch JW; Klein GJ; Yee R; Feldman RD; Brown J
J Am Coll Cardiol; 1992 Jan; 19(1):118-24. PubMed ID: 1729322
[TBL] [Abstract][Full Text] [Related]
17. Effect of isoproterenol on the anterograde refractory period of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
Wellens HJ; Brugada P; Roy D; Weiss J; Bär FW
Am J Cardiol; 1982 Jul; 50(1):180-4. PubMed ID: 7090999
[TBL] [Abstract][Full Text] [Related]
18. [The clinical significance of the ajmaline test in the noninvasive diagnosis of the Wolff-Parkinson-White syndrome].
Neuzner J; Pitschner HF; Jakob H; Schlepper M
Dtsch Med Wochenschr; 1994 Jul; 119(28-29):985-9. PubMed ID: 8039452
[TBL] [Abstract][Full Text] [Related]
19. Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
Harper RW; Whitford E; Middlebrook K; Federman J; Anderson S; Pitt A
Am J Cardiol; 1982 Dec; 50(6):1323-30. PubMed ID: 7148709
[TBL] [Abstract][Full Text] [Related]
20. A modified ajmaline test for prediction of the effective refractory period of the accessory pathway in the Wolff-Parkinson-White syndrome.
Chimienti M; Moizi M; Klersy C; Guasti L; Salerno JA
Am J Cardiol; 1987 Jan; 59(1):164-5. PubMed ID: 3812229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
